RCUS

Arcus BiosciencesC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The best post-print argument is that May 5 clarified the story rather than damaging it further: cash runway extends into at least H2 2028, near-term spend should ease as domvanalimab winds down, and management laid out a concentrated sequence of 2026-2027 RCC milestones around casdatifan plus a secondary quemliclustat option. [#8-K-2026-05-05]

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -6.2.

What can break

After STAR-121 was stopped for futility, Arcus disclosed that the domvanalimab-based combination did not improve overall survival versus pembrolizumab plus chemotherapy, raising the risk that the company has materially less late-stage diversification than it had earlier in 2026. [#8-K-2026-05-05]

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $28.00 · Bull $36.00 · Bear $17.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $37.36

Why

Momentum77 · Δ7d -6.2

Value41 · Δ7d -0.1

Sentiment44 · Δ7d +2.2

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

-6.2

Δ21d

-5.0

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+2.2

Δ21d

+9.4

Why this grade

Composite grade C. Momentum 77.5 / Value 41.1 / Sentiment 43.6

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$3.44B

Beta

0.85

Shares Out

125.77M

P/E (TTM) · Derived

-8.3

P/S (TTM)

11.14

P/FCF (TTM) · Derived

-6.39

Rev YoY

-39.3%

EPS YoY

-10.3%

Gross Margin

+96.2%

Op Margin

-156.3%

Net Debt

-$783M

Current Ratio

4.04

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology